oncology

News in brief: Negative results for anti-PD-L1 treatment in epithelial ovarian cancer; New role for Prof Sanchia Aranda; Doctors in isolation due to schools COVID-19 cases

Negative results for anti-PD-L1 treatment in epithelial ovarian cancer Results from the phase 3 JAVELIN Ovarian 100 trial do not support the use of the anti-PD-L1 monoclonal antibody avelumab in the frontline treatment setting, study investigators say. The study enrolled 998 treatment-naïve women from 25 centres with stage III–IV epithelial ovarian, fallopian tube, or peritoneal ...

Already a member?

Login to keep reading.


OR
© 2022 the limbic